Nanosonics Limited (NAN) AI Stock Analysis

• Market Cap: $1.24B
• Dividend Yield: N/A
• Average Volume (3M): 820.78K
• Price to Earnings (P/E): 59.8
• Beta (1Y): 0.40
• Revenue Growth: 15.60%
• EPS Growth: 58.74%
• Country: AU
• Employees: 466
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.03
• Shares Outstanding: 303,632,750
• 10 Day Avg. Volume: 867,075
• 30 Day Avg. Volume: 820,783
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 5.97
• Enterprise Value/Gross Profit: 7.72
• Enterprise Value/Ebitda: 49.07
• 1Y Price Target: $4.80
• Price Target Upside: 16.88% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 74 Outperform
• Price Target: AU$4.50 ▲(9.49% Upside)

Nanosonics Limited's overall stock score is driven by strong financial performance and positive earnings call sentiment. The company's robust revenue growth, profitability improvements, and strategic advancements are significant strengths. However, the high P/E ratio and mixed technical indicators slightly temper the overall score.

Nanosonics Limited Business Overview & Revenue Model

Company Description

Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

How the Company Makes Money

Nanosonics Limited primarily generates revenue through the sale and leasing of its trophon® devices, as well as the associated consumables required for operating the system, such as disinfectant cartridges. The company also earns income from service and maintenance contracts for its devices. A significant portion of its revenue comes from international sales, particularly in North America and Europe, where the adoption of the trophon® technology has been substantial. Partnerships with key medical device distributors and healthcare providers further bolster its market reach and revenue generation.

Nanosonics Limited Financial Statement Overview

Summary

Nanosonics Limited shows strong financial health with consistent revenue growth and solid balance sheet stability. Despite a decrease in net profitability and ROE, the company displays effective cash management and a robust equity position, mitigating potential financial risks.

Income Statement

Nanosonics Limited has demonstrated a consistent revenue growth trajectory with a 2.42% increase from 2023 to 2024. The Gross Profit Margin improved to 78.09% in 2024, indicating strong cost management. However, the Net Profit Margin decreased to 7.56% from 11.87% in 2023, mainly due to reduced EBIT Margin from 10.74% to 5.31%, reflecting increased operational expenses. Despite the decline in net profitability, the overall performance remains robust due to steady revenue growth.

Balance Sheet

The balance sheet of Nanosonics Limited shows a solid equity position with an Equity Ratio of 76.75% in 2024, indicating low leverage and financial stability. The Debt-to-Equity Ratio is favorable at 0.05, showcasing prudent debt management. ROE decreased to 7.12% from 12.14% in 2023, which suggests a decline in efficiency in generating profits from shareholders' equity. Nevertheless, the strong equity base mitigates potential risks, ensuring a healthy balance sheet.

Cash Flow

Cash flow analysis indicates stable cash generation, with a slight decrease in Operating Cash Flow from 2023 to 2024. The Free Cash Flow remained positive and increased slightly by 2.64% compared to the previous year, highlighting effective cash management. The Operating Cash Flow to Net Income Ratio is 1.76, demonstrating efficient conversion of income to cash. The company maintains strong liquidity, supporting its operational and strategic initiatives.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	183.97M	198.93M	171.56M	167.51M	119.73M	101.83M
Gross Profit	142.44M	155.66M	133.99M	125.66M	86.15M	74.91M
EBITDA	22.39M	31.82M	21.72M	29.50M	7.86M	15.75M
Net Income	16.56M	20.68M	12.97M	19.88M	3.74M	8.58M
Balance Sheet
Total Assets	255.03M	272.48M	237.34M	226.07M	193.24M	164.57M
Cash, Cash Equivalents and Short-Term Investments	144.48M	161.29M	129.55M	112.16M	94.51M	96.03M
Total Debt	9.17M	7.69M	9.30M	10.72M	11.71M	2.49M
Total Liabilities	66.00M	62.57M	55.14M	62.22M	54.55M	29.01M
Stockholders Equity	189.03M	209.91M	182.20M	163.86M	138.69M	135.57M
Cash Flow
Free Cash Flow	27.58M	35.26M	20.27M	19.74M	-271.00K	5.93M
Operating Cash Flow	34.93M	43.98M	22.78M	23.31M	6.70M	7.32M
Investing Cash Flow	-7.21M	-8.71M	-2.36M	-3.54M	-6.90M	-1.38M
Financing Cash Flow	-3.00M	-3.30M	-3.01M	-2.71M	-1.97M	-1.03M

Nanosonics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.11
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NAN, the sentiment is Positive. The current price of 4.11 is below the 20-day moving average (MA) of 4.15, above the 50-day MA of 4.02, and above the 200-day MA of 4.04, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 66.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NAN.

Nanosonics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SDI	76 Outperform	106.38M	8.55	0.00%	3.80%	-0.74%	16.65%
AHC	76 Outperform	131.61M	22.09	0.00%	―	39.98%	-30.04%
NAN	74 Outperform	$1.24B	59.77	10.32%	―	15.60%	58.74%
ARX	63 Neutral	231.17M	-66.34	-4.10%	―	20.36%	64.81%
TRJ	55 Neutral	114.41M	-25.60	-4.22%	―	7.38%	82.39%
CYC	42 Neutral	100.02M	-7.45	-30.89%	―	34.20%	-23.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nanosonics Limited Corporate Events

Nanosonics Announces Board Changes with Dr. McIntyre’s Departure

Nanosonics Limited announced that Dr. Lisa McIntyre will not seek re-election and will step down from the Board on November 5, 2025. Dr. McIntyre has been a significant contributor to the company, particularly as Chair of the Innovation & Development Committee. Her departure prompts the company to begin a search for a new director. Dr. Larry Marshall will take over as Chair of the Innovation & Development Committee. This leadership change reflects Nanosonics’ ongoing commitment to innovation and maintaining strong governance.

The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.

Nanosonics Limited Reports Strong Financial Growth in 2025

Nanosonics Limited reported strong financial results for the full year 2025, showcasing a 17% year-over-year increase in total revenue to $198.6 million. The company’s recurring revenue, which includes consumables and services, grew by 20% to $146.1 million, highlighting the robustness of its business model. Capital revenue also saw a 9% increase, while the gross profit margin slightly improved to 78.2%. Operating expenses rose by 10%, but the consolidated profit before tax surged by 72% to $22.3 million, indicating a solid financial performance and positive outlook for stakeholders.

The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.